People: Chelsea Therapeutics International Ltd (CHTP.PH)


CHTP.PH on Philadelphia Stock Exchange

2.42USD
18 Jun 2013
Price Change (% chg)

$-0.14 (-5.64%)
Prev Close
$2.57
Open
$2.58
Day's High
$2.58
Day's Low
$2.35
Volume
4,200
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Michael Weiser

 49 2012 Chairman of the Board

Joseph Oliveto

 45 2012 Interim President, Chief Executive Officer

J. Nick Riehle

 60 2004 Chief Financial Officer, Vice President - Administration

L. Arthur Hewitt

 59 2010 Chief Scientific Officer, Vice President

William Schwieterman

 55 2009 Chief Medical Officer, Vice President

Michael Roberts

 43 2010 Vice President - Business Development

Kevan Clemens

 67 2012 Director

William Rueckert

 59 2009 Independent Director

Roger Stoll

 69 2008 Independent Director
» Insider Trading

Biographies

Name Description

Michael Weiser

 Dr. Michael Weiser, M.D., Ph.D. has been appointed as Chairman of the Board of Chelsea Therapeutics International, Ltd., effective July 10, 2012. Dr. Weiser has served on Board of Directors since inception in April 2002, and also served as interim President from April 2002 until October 2003. Dr. Weiser founded Actin Biomed, LLC, a New York based healthcare group, in December 2006 and has served as its co-chairman since that time. Prior to that, Dr. Weiser was the Director of Research for Paramount BioScience, LLC from February 2005 until December 2006 and was the Director of Research of Paramount BioCapital Asset Management, Inc. from July 1998 until February 2005. Dr. Weiser currently serves as a director of Emisphere Technologies, Inc. and ZioPharm Oncology, Inc., both publicly traded pharmaceutical companies. He also serves as a director of several other privately held biotechnology companies. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine, where he also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience.

Joseph Oliveto

 Mr. Joseph G. Oliveto MBA,is Interim President, Chief Executive Officer of Chelsea Therapeutics International Ltd. He served as Vice President - Operations of the Company. Prior to Pappas Ventures, he served in a number of progressively senior positions at Hoffmann-La Roche, most recently as the Global Alliance Director for Roche’s licensing organization. Previous experience at Roche includes clinical development, project management, manufacturing process improvement and global business. During his tenure, he played an integral part in the success of multiple NDA filings, developed comprehensive launch programs, including those for both Pegasys and Copegus, and closed multiple licensing deals. Mr. Oliveto obtained a BA in Chemistry and an MBA from Rutgers University.

J. Nick Riehle

 Mr. J. Nick Riehle MBA, is Chief Financial Officer, Vice President - Administration of Chelsea Therapeutics International, Ltd. Prior to that he served as Chief Financial Officer at HAHT Commerce, Inc., a software company, from August 1996 until June 2003 and as an independent contractor from July 2003 until July 2004. Prior to that, Mr. Riehle served in various roles at Nortel Networks and IBM. Mr. Riehle has his Bachelor of Commerce from McGill University, his MBA from York University and earned a Certified Management Accountant (CMA) designation from Ontario, Canada.

L. Arthur Hewitt

 Dr. L. Arthur Hewitt, Ph.D. is Chief Scientific Officer, Vice President of Chelsea Therapeutics International Ltd. Dr. Hewitt was named Chief Scientific Officer in January 2010 after serving as Vice President, Drug Development since May 2004. Prior to that he served as an independent contractor from January 2003 to May 2004, as Director of Scientific Affairs at Shearwater Corporation, a drug delivery company, from October 2002 until January 2003 and as Director of Scientific Affairs for Amgen Canada from July 1991 until November 2000. During his years at Amgen, Dr. Hewitt oversaw the approval of Neupogen, Stemgen and Infergen. Dr. Hewitt obtained his Ph.D. in Pharmacology from the Medical School at the University of Montreal.

William Schwieterman

 Dr. William D. Schwieterman, M.D., is Chief Medical Officer, Vice President of Chelsea Therapeutics International Ltd. He is a rheumatologist and board-certified internist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a number of different types of molecules. After leaving the FDA, he acted as an independent consultant to biotechnology and pharmaceutical companies, focusing on clinical drug development and regulatory matters. He currently serves on the board of directors of OXiGENE, Inc., a publicly traded company, and Neumedics, Inc., a privately held drug development company. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati.

Michael Roberts

 Mr. Michael J. Roberts, Ph.D., is Vice President - Business Development of Chelsea Therapeutics International Ltd. He joined the company from Nektar Therapeutics where he was Director of Business Development for their Molecule Engineering technology. Prior to this, he was Manager of Biopharmaceutical Research at Shearwater Corporation where he led and was involved in the development of preclinical drug candidates from initial stages of research through Phase I clinical study. Dr. Roberts obtained his Ph.D. in Materials Science from the University of Alabama in Huntsville and B.S. in Chemical Engineering from Pennsylvania State University.

Kevan Clemens

 Dr. Kevan Clemens, Ph.D., serves as Director of Chelsea Therapeutics International, Ltd. He resigned as Independent Chairman of the Board of the Company, effective July 10, 2012. Dr. Clemens has served on Board of Directors since September 2004. In 2004, Dr. Clemens retired after 30 years of experience in the pharmaceutical industry. In his last position as Executive VP/Business Director at Hoffmann-La Roche, he ran the Global Oncology business that included Strategic/Business plans and the Development/Marketing of the products. Prior to that he was Global Head of Specialty Care, Global Head of Project Management and the Head of Clinical Operations for North and South America. Dr. Clemens worked for 25 years at Syntex and Roche in Development, Sales and Marketing positions including Head of Pharmacoeconomics & Pricing. Dr. Clemens also served on the board of directors of Kosan Biosciences Incorporated from 2005 to 2008. Dr. Clemens obtained his Ph.D. in Chemistry from the University College London.

William Rueckert

 Mr. William Dodge Rueckert, B.A ., is Independent Director of Chelsea Therapeutics International, Ltd., July 2009. Mr. Rueckert is the Managing Member of Oyster Management Group LLC, an investment fund specializing in community banks and a director of Novogen Limited, a publicly listed Australian drug development company. Prior to his current positions, from 1991 to 2006 he was President and director of Rosow & Company, a private investment firm based in Connecticut. From 1988 until 1990, he held positions as Treasurer of Moore & Munger, Inc., a company with interests in the petroleum and resort development industries. Prior to that, he was President of United States Oil Company, a publicly traded oil exploration business. Before becoming a director of Novogen Limited in 2009, he served as a member of the Board of Directors of Marshall Edwards, Inc., a subsidiary of Novogen Limited from 2007 until 2009. From 2006 until 2008 Mr. Rueckert was a Director of Nano Mask Inc., a public manufacturer and marketer of respiratory filtration devices. Mr. Rueckert has served as a director of Glycotex, Inc. since 2006 and is also a director of Rapid Pathogen Screening, Inc. and Fairfield County Bank, all privately held companies. Among his many civic associations, Mr. Rueckert is director and president of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City and Chairman of the Board of the Trustees of Teachers College, Columbia University. Mr. Rueckert has a Bachelor of Arts degree from the University of New Hampshire.

Roger Stoll

 Dr. Roger G. Stoll, Ph.D. is Independent Director of Chelsea Therapeutics International, Ltd., since February 2008. Dr. Stoll currently serves as Executive Chairman of Cortex Pharmaceuticals, a publicly traded company. From August 2002 to August 2008, Dr. Stoll was the Chairman, President and CEO of Cortex Pharmaceuticals. Prior to that, he was the Executive Vice President of Fresenius Medical Care—North America, where he oversaw both the dialysis products and laboratory services groups. From 1991 to 1998, Dr. Stoll was Chief Executive of Ohmeda, Inc. and served on the board of directors of the BOC Group, Plc in the UK, the parent of Ohmeda. Prior to that, Dr. Stoll held positions of increasing responsibility within the pharmaceutical industry including President of the Consumer Health Care Group of Miles Laboratories, Executive Vice President and General Manager of the worldwide Diagnostics Business Group at Bayer AG, Director of Clinical Pharmacology and President of the American Critical Care Division for American Hospital Supply Corp (now Baxter International). He began his career at the Upjohn Company where he conducted human pharmacokinetic and drug metabolism clinical trials in all phases of drug development. Dr. Stoll currently serves on the Board of Directors of Cortex Pharmaceuticals, Inc. and Delcath Systems, Inc., both publicly traded companies. Dr. Stoll received his bachelor’s degree in pharmacy from Ferris State University, a Ph.D. in Biopharmaceutics from the University of Connecticut, and performed postdoctoral studies in pharmacokinetics and drug metabolism at the University of Michigan.

Basic Compensation

Name Fiscal Year Total

Michael Weiser

 --

Joseph Oliveto

 564,861

J. Nick Riehle

 528,218

L. Arthur Hewitt

 609,210

William Schwieterman

 693,204

Michael Roberts

 512,595

Kevan Clemens

 --

William Rueckert

 --

Roger Stoll

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Michael Weiser

 0 0

Joseph Oliveto

 0 0

J. Nick Riehle

 156,963 271,362

L. Arthur Hewitt

 127,606 176,203

William Schwieterman

 0 0

Michael Roberts

 0 0

Kevan Clemens

 0 0

William Rueckert

 0 0

Roger Stoll

 0 0

Insider Trading

Name Shares Traded Price

AUSTIN JOSIAH T

 439,308 $0.92

AUSTIN JOSIAH T

 249,249 $0.95

AUSTIN JOSIAH T

 399,414 $1.05

AUSTIN JOSIAH T

 139,653 $1.05

AUSTIN JOSIAH T

 230,407 $1.00

AUSTIN JOSIAH T

 235,009 $1.07

AUSTIN JOSIAH T

 154,836 $1.18

WEISER MICHAEL

 4,900 $1.32

WEISER MICHAEL

 100 $1.32

LAU JOHNSON YIU NAM

 8,000 $1.31

AUSTIN JOSIAH T

 4,000 $4.50

AUSTIN JOSIAH T

 13,900 $4.46

AUSTIN JOSIAH T

 4,000 $4.43

AUSTIN JOSIAH T

 40,000 $4.80

STOLL ROGER G

 12,000 $0.00

WEISER MICHAEL

 18,593 $2.88

SCHWIETERMAN WILLIAM D

 45,141 $4.46

AUSTIN JOSIAH T

 2,100 $4.37
» Full list on Insider Trading
Search Stocks